IQ-AI Limited Imaging Biometrics Partners with AI Metrics (2041Z)
09 Enero 2020 - 01:00AM
UK Regulatory
TIDMIQAI
RNS Number : 2041Z
IQ-AI Limited
09 January 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
Imaging Biometrics Partners with AI Metrics
Imaging Biometrics(R), LLC ("IB"), a subsidiary of IQ-AI Limited
(LON:IQAI), announced today that is has entered into a global
distribution agreement with AI Metrics, LLC (Birmingham, AL). The
agreement grants IB non-exclusive global rights to market and
distribute AI Metrics' LSN image analysis product. LSN is a
first-to-market platform designed by AI Metrics as a virtual liver
biopsy, evaluating liver surface nodularity (LSN) to assess Chronic
Liver Disease (CLD) using commonly acquired CT images.
Leading up to this agreement, IB assisted AI Metrics in the
development of the LSN software by working closely with AI Metrics'
CEO, Dr. Andrew Smith, MD, who provided valuable feedback and
enhancement suggestions to IB's development team. IB also offered
its regulatory expertise and is assisting AI Metrics in obtaining
CE Mark and FDA 510(k) market clearance in Europe and the U.S.,
respectively.
"We are excited about partnering with Imaging Biometrics as we
introduce LSN technology to the worldwide market, " said Dr. Andrew
Smith, CEO of AI Metrics. "Their development efforts have been
integral to bringing LSN from promising research to commercial
introduction, and the continuity of our relationship moving forward
will ensure that LSN can quickly gain rapid and widespread
utilization."
Chronic liver disease (CLD) is a serious condition that includes
inflammation, progressive stages of fibrosis, and cirrhosis.
Clinically silent, over 20 million deaths worldwide are attributed
to CLD with the majority of those resulting from non-alcoholic
fatty liver disease. AI Metrics has developed its proprietary LSN
Software to non-invasively assess the nodules, or bumps, on the
liver's surface. This information, when used by trained clinicians,
may aid in the diagnosis and staging of CLD.
Currently, clinicians assess patient liver condition via
surgical biopsy, which is prone to sampling error, pain, bleeding,
and other complications. In contrast, LSN analysis uses common CT
scanning technology and proprietary software for accurate, low risk
assessment of CLD. While other non-invasive imaging approaches are
available, such as magnetic resonance elastography and ultrasound
elastography, both require non-standard imaging technology, and
patient fasting beforehand.
"LSN fits perfectly with IB's product portfolio and we look
forward to helping deploy LSN worldwide," said Michael Schmainda,
Director of IB. "The ability to non-invasively and accurately
assess CLD is exciting for clinicians and will ultimately benefit
patients," Schmainda added.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
About AI Metrics
AI Metrics is an early stage company creating transformational
image analysis technology that positions radiologists to be the
most efficient, valuable clinicians in the patient care continuum.
Founded by emerging radiology leader Dr. Andrew Smith, the Company
is developing AI-driven innovations to enhance workflow speed and
reduce costs, while improving data quality for clinical and
research efforts, and ultimately, for improved physician
collaboration and patient care and communication. For more
information about AI Metrics, visit the company's website at
www.aimetrics.com.
About Imaging Biometrics
Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualization and analytical solutions that
enable clinicians to better diagnose and treat diseases with
greater confidence. Through close collaboration with top
researchers and clinicians, sophisticated advancements are
translated into platform-independent software plug-ins which can
extend the base functionality of workstations, imaging systems,
PACS, or medical viewers. By design, IB's advanced visualization
software seamlessly integrates into routine workflows. For more
information about Imaging Biometrics, visit the company's website
at www.imagingbiometrics.com.
About IQ-AI
IQ-AI Limited (Ticker:IQAI) is the parent company of Imaging
Biometrics(R) focused on advanced and state of the art medical
software and services. (www.iq-ai.ltd).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRZZGGMVRLGGZM
(END) Dow Jones Newswires
January 09, 2020 02:00 ET (07:00 GMT)
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024